Scarica l'app Stockscreener
37.25
1.18%
-0.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$37.64
Aprire:
$37.4
Volume 24 ore:
434.73K
Relative Volume:
0.26
Capitalizzazione di mercato:
$4.44B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-7.0817
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
+0.04%
1M Prestazione:
+10.57%
6M Prestazione:
-24.80%
1 anno Prestazione:
-35.77%
Intervallo 1D:
$36.61
$38.06
Intervallo di 1 settimana:
$35.50
$38.59
Portata 52W:
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
37.17 | 4.32B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.65 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.62 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.49 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
679.01 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.56 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
What are the latest earnings results for Cytokinetics IncorporatedExpert Picks Outlook For Beginners - jammulinksnews.com
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cytokinetics, Incorporated (CYTK) Regarding Possible Securities Fraud Violations - ACCESS Newswire
What institutional investors are buying Cytokinetics Incorporated stockFree Stock Forecasts That Work - jammulinksnews.com
Levi & Korsinsky Announces an Investigation on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Institutional Tools Highlight Unusual Flow in Cytokinetics IncorporatedWeekly Chart Analysis With Entry Advice Provided - metal.it
Raymond James downgrades Cytokinetics stock rating to Market Perform By Investing.com - Investing.com Canada
Cytokinetics, Incorporated Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsCYTK - ACCESS Newswire
Cytokinetics Incorporated Stock Support and Resistance Levels You Should KnowRisk Controlled Picks With Real Returns Outlined - metal.it
Why Cytokinetics Incorporated stock attracts strong analyst attentionEarnings Play Trade Plan With Alerts Shared - metal.it
Cytokinetics Incorporated Earnings Report Breakdown: What Investors Should KnowInvestment Playbook for Growing Markets Shared - metal.it
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - MSN
Cytokinetics, Incorporated (CYTK) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
What makes Cytokinetics Incorporated stock price move sharplyBuild wealth faster with consistent investment plans - jammulinksnews.com
How strong is Cytokinetics Incorporated company’s balance sheetUnlock exclusive stock market forecasts - jammulinksnews.com
What are analysts’ price targets for Cytokinetics Incorporated in the next 12 monthsDiscover undervalued opportunities early - jammulinksnews.com
Cytokinetics (CYTK): Is the FDA Delay a Buying Opportunity for Aficamten's Long-Term Payoff? - AInvest
Levi & Korsinsky Reminds Cytokinetics, Incorporated Investors of the Ongoing Investigation into Potential Violations of Securities LawsCYTK - ACCESS Newswire
Cytokinetics Incorporated Stock Analysis and ForecastSpectacular growth rates - PrintWeekIndia
Cytokinetics to Announce Second Quarter Results On August 7, 2025 - Yahoo Finance
What risks could impact Cytokinetics Incorporated stock performanceExceptional trading performance - jammulinksnews.com
Cytokinetics Sets Key Q2 Earnings Date: What Investors Should Watch on August 7 - Stock Titan
Top Executive Sells Cytokinetics Stock in a Major Move - TipRanks
What drives Cytokinetics Incorporated stock priceRapid portfolio appreciation - Autocar Professional
What analysts say about Cytokinetics Incorporated stockFree Stock Market Knowledge Sharing - jammulinksnews.com
Is Cytokinetics Incorporated a good long term investmentOutstanding trading profits - jammulinksnews.com
Shareholders that lost money on Cytokinetics, Incorporated (CYTK) should contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
Cytokinetics, Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cytokinetics, Incorporated (CYTK) - ACCESS Newswire
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics Awards 220,000 Shares in Employee Stock Grants at $38.68 Strike Price - Stock Titan
Cytokinetics’ Aficamten Study: A New Hope for Pediatric Heart Patients - TipRanks
Cytokinetics CEO Makes a Significant Stock Move! - TipRanks
Cytokinetics (CYTK) CEO Blum sells $190k in stock By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) CEO Blum sells $190k in stock - Investing.com
CYTK ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytokinetics Inc Azioni (CYTK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Jul 22 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
142,610 |
| Malik Fady Ibraham | EVP Research & Development |
Jul 22 '25 |
Sale |
37.47 |
2,000 |
74,940 |
140,610 |
| Blum Robert I | President & CEO |
Jul 14 '25 |
Sale |
38.15 |
5,000 |
190,750 |
393,108 |
0.12%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):